Combatting Burkholderia Cepacia

Combatting Burkholderia Cepacia

The Burkhoderia Cepacia complex (Bcc) poses significant health risks for those with Cystic Fibrosis (CF). Plus, its ability to spread via patients, and non-sterile, water-based products (due to biofilm formation) makes it a major concern in healthcare facilities and the pharmaceutical industry.



A serious threat to CF patients

 

Over 80% of CF patients face respiratory failure from chronic infections and inflammation. While global guidelines are lacking, some countries, including the USA 🇺🇸 and China 🇨🇳, recommend microbiological monitoring every 3-6 months.


Thankfully, there’s hope on the horizon with promising new drug developments!

 

Industry Alert of Bcc contamination

 

More than 50 pharmaceutical companies have experienced recalls due to Bcc contamination in recent years.

 

In 2024, the renowned skincare brand Nuxe recalled batches of their 400ml Very Rose 3-in-1 micellar water in France due to possible Bcc contamination.

 

 

 

Innovative Detection with CHROMagar™ B.cepacia

 

Our solution CHROMagar™ B.cepacia is a selective medium for the detection and enumeration of the Burkholderia Cepacia complex, delivering rapid, clear results with high-intensity colony color. This is vital for pharmaceutical and clinical monitoring and safety.

Key features include:

  • Sensitivity: Approximately 100%

     

    Specificity 95 %

     

     

     

    Advantages of CHROMagar™ B.cepacia

     

  • High Intensity: Burkholderia cepacia complex (BCC) colonies develop with an intense green- blue colony colour, clearly visible to the naked eye.

     

    Limits Contaminants : Mold is largely inhibited.

     

    All in one : To save time, the pre-weighed medium powder can be added to distilled water. No supplement is  required.

     

    Diverse areas of application: It allows for the cultivation of clinical and pharmaceutical samples, facilitating the diagnosis of Bcc infections.

     

    Samples: Bronchoalveolar lavages, sputum, nasopharyngeal aspirations, and oropharyngeal swabs, urine and stools samples. Non-sterile products and purified water.

  •  

 

 

References

1.Somayaji et al. 2020. Ann Am Thorac Soc

2.Hedary et al. 2024. Cureus.

3.Shmarina et al. 2024. Front Cell Infect Microbiol.

4.https://www.ecfs.eu/

5.Bhagirath et al. 2016. BMC Pulm Med.

6.Practical Guidance for Clinical Microbiology Laboratories , Chinese Alliance for Rare Lung Diseases

7.Tavares et al. 2020. Clin Microbiol Rev.

8.Duonget al. 2024. PLoS One.

9.Häfligeret al. 2020 Infect Prev Pract.

10.Guo et al. 2017. Am J Infect Control. , Gleeson et al. 2019. Perit Dial Int., Greendyke et al. 2018. Open Forum Infect Dis., Marquez et al. 2017. Infect Control Hosp Epidemiol., Mali et al. 2017. Indian J Med Microbiol., Sommerstein et al. 2017. Euro Surveill., Clark et al. 2018. Intern Med, J.Rastogi et al. 2019. Int J Infect Dis., Zou et al. 2020. Am J Infect Control., Brooks et al. 2019. Clin Infect Dis., Gupta et al. 2018. Indian J Anaesth., Abdelfattah et al. 2018. J Hosp Infect., Yamunadevi et al. 2018. J Hosp Infect., Becker et al. 2018. Euro Surveill., Jin et al. 2024. Gastrointest Endosc., Huong et al. 2024. PLoS One., Kimani et al. 2024. PLoS One., Shui-Kuen Cheng et al. 2024. Infect Prev Pract., Salamanca-Pachon et al. 2023. Microorganisms., Singhal et al. 2023. Indian J Med Microbiol., Al Zunitan et al. 2023. J Hosp Infect., Matsumoto et al. 2023. J Water Health., Hudson et al. 2022. MMWR Morb Mortal Wkly Rep., Sridharan et al. 2021. Indian J Med Microbiol., Bilgin et al. 2021. Antimicrob Resist Infect Control., Dos Santos Saalfeld et al. 2021. Infect Control Hosp Epidemiol., Wong et al. 2020. Emerg Infect Dis., Tavares et al. 2020. Front Bioeng Biotechnol., Dos Santos Saalfeld et al. 2020. Infect Control Hosp Epidemiol., Solaimalai et al. 2019. Indian J Med Microbiol., Lo Priore et al. 2020. Infect Prev Pract., Riquena et al. 2019. J Bras Pneumol., Frank et al. 2019. Pan Afr Med J., Song et al. 2018. J Hosp Infect.

11.Masotti et al. 2021. RICAI